treatment

Multiple sclerosis (MS) patients treated with Betaseron (interferon beta-1b) had over 90% treatment compliance — the percentage of doses administered — over one year, according to a study of data collected by the BETACONNECT autoinjector and the myBETAapp. After one year, the number of patients still using Betaseron…

The U.S. Food and Drug Administration (FDA) has cleared a Phase 1b/2a trial of PIPE-307, Pipeline Therapeutics‘ investigational myelin-restoring treatment, in people with relapsing-remitting multiple sclerosis (RRMS). The trial will enroll about 45 RRMS patients from multiple U.S. sites who will be randomized to receive either three months…

A team of researchers has discovered that the key to bypassing the blood-brain barrier — a semipermeable border that protects the brain against toxins in the blood but also blocks potential treatments — is the Unc5B receptor in the endothelial cells that line the tiny blood vessels in the brain.

Stem Cell Transplant Gaining Ground as MS Therapy Option This comprehensive look at stem cell transplants by Multiple Sclerosis News Today writer Hawken Miller is one of the best overviews of the possible benefits and dangers and the current status of autologous hematopoietic stem cell transplantation (aHSCT) that…

A researcher in Barcelona, Spain, has been chosen to receive the 2022 John Dystel Prize for his work advancing the understanding, diagnosis, and treatment of multiple sclerosis (MS). The $40,000 prize, given jointly by the National MS Society and the American Academy of Neurology (AAN), will be…

A four-protein complex, or tetramer, of the protein STAT5 is involved in the development of multiple sclerosis (MS)-like autoimmune disease in mice, a new study shows. The findings point to this protein complex and its signaling pathway as a potential treatment in MS and other autoimmune conditions, scientists noted.

Higher doses of temelimab were generally safe and resulted in beneficial trends on key neurodegeneration markers in adults with relapsing forms of multiple sclerosis (MS) who already were on rituximab treatment, according to top-line data from the ProTEct-MS Phase 2 clinical trial. While the study’s small size…

Treatment with cannabis-based medications may ease muscle spasms, decrease pain, and aid in sleep for people with multiple sclerosis (MS), but more research is needed to evaluate the potential benefits of cannabis use. That is the finding of a team of U.S. researchers who published a review paper, “…

Nothing was working for Jennifer Stansbury Koenig, who was diagnosed with relapsing-remitting multiple sclerosis (RRMS) in 2010 the day before she learned she was pregnant. The first disease-modifying therapy (DMT) Koenig started in 2013, Tecfidera (dimethyl fumarate), an oral capsule developed and marketed by Biogen, made her…

A measure of the nose’s sensitivity to smell could be used to detect whether treatments for relapsing multiple sclerosis (MS) are working or not, a new study indicates. The scientists noted that their results need to be validated through further study, but said the findings suggest that a smell…

For the first time, researchers have brought to light the precise three-dimensional structure of Mayzent (siponimod) as it binds to its molecular target, the sphingosine 1-phosphate receptor 1 (S1P1). These findings are expected to aid in developing next-generation MS therapeutics with better selectivity for S1P1, enhancing their potency while reducing…

NervGen Pharma has been cleared to enroll a second group of healthy volunteers into the multiple ascending dose portion of its Phase 1 clinical trial of NVG-291, a therapeutic candidate for multiple sclerosis (MS). The trial’s Safety Review Committee approved the second group after seeing promising safety data…

Initial treatment with Novantrone (mitoxantrone) can reduce the risk of relapses and worsening disability in people with highly active relapsing-remitting multiple sclerosis (RRMS), according to a 10-year study from France. “Our results support the short-term use of [Novantrone], followed by a maintenance therapy for patients with early highly…

Six months of treatment with foralumab, an experimental nasal spray, safely and effectively improved motor and cognitive function while easing immune activation and inflammatory responses in a person with secondary progressive multiple sclerosis (SPMS), Tiziana Life Sciences, the therapy’s developer, announced. The patient — the first with MS to…

PIPE-307, an investigational myelin-restoring medication being developed by Pipeline Therapeutics for the treatment of multiple sclerosis (MS), appears to be safe and well tolerated in healthy adults. The results are from a Phase 1 clinical trial (NCT04725175) that evaluated the safety and tolerability of PIPE-307 in 70…

Cionic has received authorization from the U.S. Food and Drug Administration (FDA) to market its lightweight, leg-worn Neural Sleeve to improve walking in people with multiple sclerosis (MS) and other conditions that affect mobility. The decision comes four months after the company submitted the device — the first to…

A short-term ketogenic diet, which dramatically cuts carbohydrate consumption, is safe and results in significant improvements in people with relapsing-remitting multiple sclerosis (RRMS), a small study in patients reported. “Our study provides evidence that a ketogenic diet is safe and beneficial, reducing some symptoms for people with MS, when…

#ACTRIMS2022 – Cognitive Training Paired With tDCS Aids Patients A treatment to clear “cog fog” would be welcomed by many people with MS. Over 75% of us are troubled by cognitive problems. In this study, adding painless transcranial direct current stimulation to standard cognitive training improved results when compared…

Administering the stem cell therapy NG-01 — designed to have neuroprotective and neuro-regenerative properties — directly into the spinal canal can significantly reduce the levels of neurofilament light chain (NfL), a neuronal damage biomarker, in people with active, progressive forms of multiple sclerosis (MS). These are the new…

Tolebrutinib, an investigative inhibitor of Bruton’s tyrosine kinase (BTK) being developed by Sanofi to treat all forms of multiple sclerosis (MS), shows the potential to be more potent than other BTK inhibitors also in advanced clinical trials, scientists reported. The findings, based on preclinical data, were shared at the Americas…

Hormonal changes over time — and especially those around menopause — are often associated with disability worsening in multiple sclerosis (MS) patients, which suggests that sex-specific hormone therapies may be useful in MS treatment. Burcu Zeydan, MD, assistant professor of neurology and radiology at Mayo Clinic, provided an overview…

“I close my eyes/ Only for a moment then the moment’s gone/ All my dreams pass before my eyes, a curiosity.” — Kansas, “Dust in the Wind”  The dark cloud of fatigue first swept through my mind toward the end of 2018. I was no stranger to physical fatigue,…

People with multiple sclerosis (MS) who are treated with Mavenclad (cladribine) are less likely to experience a disease relapse than those who are treated with Gilenya (fingolimod), Tecfidera (dimethyl fumarate), or Aubagio (teriflunomide), according to an analysis of real-world data. The findings were presented at the Americas Committee…

Researchers developed a new mouse model that more closely captures a specific type of inflammation characteristic of progressive multiple sclerosis (MS) — and found, in experiments, that treatment with an oral medication called evobrutinib can lessen disease activity. This new mouse model may help scientists in MS to better study…

Undergoing a stem cell transplant, a procedure that aims to “reset” a person’s immune system, can reduce relapse rates and ease disability in people with multiple sclerosis (MS), new data show. The findings suggest that such a transplant — fully, autologous hematopoietic stem cell transplantation or aHSCT — is…

A matrix protein called fibulin-2, which is increased in multiple sclerosis (MS) lesions, blocks the activity of oligodendrocytes, the cells responsible for making myelin. Blocking this protein may be a promising approach to restore myelin in people with the neurodegenerative disease, a study in mice showed. The data was…

Machine learning — using computer algorithms — can be used to identify people with primary progressive multiple sclerosis (PPMS) who are more likely to respond to treatment, a new study shows. The ability to predict treatment response could allow clinical trials to be designed more efficiently, researchers said. Jean-Pierre…

  Synaptogenix announced plans to advance bryostatin-1, its lead candidate, into clinical trials for multiple sclerosis (MS), marking the third neurological disease the small molecule therapy is being developed to potentially treat. “Multiple sclerosis joins Alzheimer’s disease (“AD”) and Fragile X syndrome as our third indication with potential clinical…

Levels of a protein called neurofilament light chain (NfL) in the blood can be used to predict the risk of future disease activity in people with multiple sclerosis (MS), according to a new study. The results also suggest that changes in NfL levels could be used to deduce the extent…

Fatigue Severity in MS Predicted by Shrinkage of Certain Brain Regions For several years, I’ve been a believer, along with many neurologists, in the theory that it’s best to treat MS as quickly and effectively as possible. Though directed at only fatigue indicators, this research looking at brain atrophy…